A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs AMG-701 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 18 Oct 2017 Last checked against ClinicalTrials.gov record.
- 13 Oct 2017 Planned initiation date changed from 2 Oct 2017 to 30 Oct 2017.
- 22 Sep 2017 New trial record